The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform
Pavlos Toutouzas - One of the best experts on this subject based on the ideXlab platform.
-
Autologous Vein graft-coated stents for the treatment of thrombus-containing coronary artery lesions
Catheterization and cardiovascular diagnosis, 1997Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Recent studies have shown that stents may have a potential role in the treatment of thrombus-containing lesions. We report on the application of an Autologous Vein graft-coated stent (AVGCS) as the primary therapeutic modality for acute myocardial infarction in 10 patients. AVGCS delivery and deployment were successful and uneventful. Mean minimal lumen diameter and TIMI trial flow grade increased significantly (from 0.04 +/- 0.09 mm pre-AVGCS to 3.02 +/- 0.32 mm post-AVGCS, and from 10 patients with flow grade 0-1 pre-AVGCS to 10 patients with flow grade 3 post-AVGCS, respectively). Ten-day angiogram revealed maintenance of the immediate results. Nine patients had a negative exercise stress test 2 mo post-AVGCS, and at a mean follow-up of 30 +/- 7 weeks, all 9 were symptom-free. One patient, 3 wk after implantation and while being hospitalized for hypovolemic shock, developed recurrent infarction. These favorable preliminary outcomes suggest that AVGCS may play a useful role in the treatment of thrombus-containing lesions.
-
Stents wrapped in Autologous Vein: an experimental study.
Journal of the American College of Cardiology, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Panayiotis Karayannakos, Pavlos Toutouzas, Michael M. Gravanis, Keith A. RobinsonAbstract:Abstract Objectives. A new type of coated stent, consisting of a conventional stent covered by an Autologous Vein graft, was developed at our institution. Background. Coated stents are under investigation to address stenting limitations. However, experimental implantation of coated stents covered by Autologous tissue has not been reported. Methods. An Autologous Vein graft was removed and carefully prepared. Subsequently, a Palmaz stent was covered by the Vein graft both internally and externally. Twenty-seven stents were implanted in the normal iliac arteries of 27 pigs weighing 18 to 33 kg. In 15 of the pigs, 15 noncoated Palmaz stents were implanted in the contralateral artery; these animals served as the control group. The animals were followed up angiographically for a period ranging from 7 days to 6 months. At the time of death, the stented segments were removed, and histomorphometric analysis was performed. Results. Autologous Vein graft-coated stent preparation and implantation was feasible and uncomplicated. In both stents, angiographic follow-up revealed the absence of thrombosis, except for two cases of subacute thrombosis in the control group. The thickness of the intimal layer was greater in the coated stents and seems to be due to the existence of the internal Vein layer ([mean ± SD] 0.57 ± 0.12 vs. 0.27 ± 0.13 mm, p = 0.001). The arterial media of the coated stent segments was thinner than that in the control group (0.14 ± 0.03 vs. 0.18 ± 0.01 mm, p = 0.02). Conclusions. The Autologous Vein graft-coated stent seems to be nonthrombogenic, and only minimal hyperplasia was observed in the pigs. Further studies are needed to explore the efficacy of this technique in humans.
-
Autologous Vein graft-coated stent for treatment of coronary artery disease.
Catheterization and cardiovascular diagnosis, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Acute or subacute thrombosis and late restenosis remain the main limitations of permanent stenting. In an effort to address these limitations, an Autologous Vein graft-coated stent (AVGCS) was developed at our institution. This stent consists of a conventional stent (Palmaz or Palmaz-Schatz, Johnson and Johnson), which is covered by an Autologous Vein graft. After successful experimental implantation, we report here the immediate results of the percutaneous implantation of AVGCS in 7 patients with coronary artery disease (6 de novo lesions and 1 bailout case). The results of this preliminary study indicate that the preparation of the AVGCS is easy and feasible. The implantation of the AVGCS was uncomplicated, and the immediate angiographic results were excellent. This new type of coated stent may be useful in addressing current limitations of balloon angioplasty.
Christodoulos Stefanadis - One of the best experts on this subject based on the ideXlab platform.
-
Autologous Vein graft-coated stents for the treatment of thrombus-containing coronary artery lesions
Catheterization and cardiovascular diagnosis, 1997Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Recent studies have shown that stents may have a potential role in the treatment of thrombus-containing lesions. We report on the application of an Autologous Vein graft-coated stent (AVGCS) as the primary therapeutic modality for acute myocardial infarction in 10 patients. AVGCS delivery and deployment were successful and uneventful. Mean minimal lumen diameter and TIMI trial flow grade increased significantly (from 0.04 +/- 0.09 mm pre-AVGCS to 3.02 +/- 0.32 mm post-AVGCS, and from 10 patients with flow grade 0-1 pre-AVGCS to 10 patients with flow grade 3 post-AVGCS, respectively). Ten-day angiogram revealed maintenance of the immediate results. Nine patients had a negative exercise stress test 2 mo post-AVGCS, and at a mean follow-up of 30 +/- 7 weeks, all 9 were symptom-free. One patient, 3 wk after implantation and while being hospitalized for hypovolemic shock, developed recurrent infarction. These favorable preliminary outcomes suggest that AVGCS may play a useful role in the treatment of thrombus-containing lesions.
-
Stents wrapped in Autologous Vein: an experimental study.
Journal of the American College of Cardiology, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Panayiotis Karayannakos, Pavlos Toutouzas, Michael M. Gravanis, Keith A. RobinsonAbstract:Abstract Objectives. A new type of coated stent, consisting of a conventional stent covered by an Autologous Vein graft, was developed at our institution. Background. Coated stents are under investigation to address stenting limitations. However, experimental implantation of coated stents covered by Autologous tissue has not been reported. Methods. An Autologous Vein graft was removed and carefully prepared. Subsequently, a Palmaz stent was covered by the Vein graft both internally and externally. Twenty-seven stents were implanted in the normal iliac arteries of 27 pigs weighing 18 to 33 kg. In 15 of the pigs, 15 noncoated Palmaz stents were implanted in the contralateral artery; these animals served as the control group. The animals were followed up angiographically for a period ranging from 7 days to 6 months. At the time of death, the stented segments were removed, and histomorphometric analysis was performed. Results. Autologous Vein graft-coated stent preparation and implantation was feasible and uncomplicated. In both stents, angiographic follow-up revealed the absence of thrombosis, except for two cases of subacute thrombosis in the control group. The thickness of the intimal layer was greater in the coated stents and seems to be due to the existence of the internal Vein layer ([mean ± SD] 0.57 ± 0.12 vs. 0.27 ± 0.13 mm, p = 0.001). The arterial media of the coated stent segments was thinner than that in the control group (0.14 ± 0.03 vs. 0.18 ± 0.01 mm, p = 0.02). Conclusions. The Autologous Vein graft-coated stent seems to be nonthrombogenic, and only minimal hyperplasia was observed in the pigs. Further studies are needed to explore the efficacy of this technique in humans.
-
Autologous Vein graft-coated stent for treatment of coronary artery disease.
Catheterization and cardiovascular diagnosis, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Acute or subacute thrombosis and late restenosis remain the main limitations of permanent stenting. In an effort to address these limitations, an Autologous Vein graft-coated stent (AVGCS) was developed at our institution. This stent consists of a conventional stent (Palmaz or Palmaz-Schatz, Johnson and Johnson), which is covered by an Autologous Vein graft. After successful experimental implantation, we report here the immediate results of the percutaneous implantation of AVGCS in 7 patients with coronary artery disease (6 de novo lesions and 1 bailout case). The results of this preliminary study indicate that the preparation of the AVGCS is easy and feasible. The implantation of the AVGCS was uncomplicated, and the immediate angiographic results were excellent. This new type of coated stent may be useful in addressing current limitations of balloon angioplasty.
Ioannis Kallikazaros - One of the best experts on this subject based on the ideXlab platform.
-
Autologous Vein graft-coated stents for the treatment of thrombus-containing coronary artery lesions
Catheterization and cardiovascular diagnosis, 1997Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Recent studies have shown that stents may have a potential role in the treatment of thrombus-containing lesions. We report on the application of an Autologous Vein graft-coated stent (AVGCS) as the primary therapeutic modality for acute myocardial infarction in 10 patients. AVGCS delivery and deployment were successful and uneventful. Mean minimal lumen diameter and TIMI trial flow grade increased significantly (from 0.04 +/- 0.09 mm pre-AVGCS to 3.02 +/- 0.32 mm post-AVGCS, and from 10 patients with flow grade 0-1 pre-AVGCS to 10 patients with flow grade 3 post-AVGCS, respectively). Ten-day angiogram revealed maintenance of the immediate results. Nine patients had a negative exercise stress test 2 mo post-AVGCS, and at a mean follow-up of 30 +/- 7 weeks, all 9 were symptom-free. One patient, 3 wk after implantation and while being hospitalized for hypovolemic shock, developed recurrent infarction. These favorable preliminary outcomes suggest that AVGCS may play a useful role in the treatment of thrombus-containing lesions.
-
Stents wrapped in Autologous Vein: an experimental study.
Journal of the American College of Cardiology, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Panayiotis Karayannakos, Pavlos Toutouzas, Michael M. Gravanis, Keith A. RobinsonAbstract:Abstract Objectives. A new type of coated stent, consisting of a conventional stent covered by an Autologous Vein graft, was developed at our institution. Background. Coated stents are under investigation to address stenting limitations. However, experimental implantation of coated stents covered by Autologous tissue has not been reported. Methods. An Autologous Vein graft was removed and carefully prepared. Subsequently, a Palmaz stent was covered by the Vein graft both internally and externally. Twenty-seven stents were implanted in the normal iliac arteries of 27 pigs weighing 18 to 33 kg. In 15 of the pigs, 15 noncoated Palmaz stents were implanted in the contralateral artery; these animals served as the control group. The animals were followed up angiographically for a period ranging from 7 days to 6 months. At the time of death, the stented segments were removed, and histomorphometric analysis was performed. Results. Autologous Vein graft-coated stent preparation and implantation was feasible and uncomplicated. In both stents, angiographic follow-up revealed the absence of thrombosis, except for two cases of subacute thrombosis in the control group. The thickness of the intimal layer was greater in the coated stents and seems to be due to the existence of the internal Vein layer ([mean ± SD] 0.57 ± 0.12 vs. 0.27 ± 0.13 mm, p = 0.001). The arterial media of the coated stent segments was thinner than that in the control group (0.14 ± 0.03 vs. 0.18 ± 0.01 mm, p = 0.02). Conclusions. The Autologous Vein graft-coated stent seems to be nonthrombogenic, and only minimal hyperplasia was observed in the pigs. Further studies are needed to explore the efficacy of this technique in humans.
-
Autologous Vein graft-coated stent for treatment of coronary artery disease.
Catheterization and cardiovascular diagnosis, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Acute or subacute thrombosis and late restenosis remain the main limitations of permanent stenting. In an effort to address these limitations, an Autologous Vein graft-coated stent (AVGCS) was developed at our institution. This stent consists of a conventional stent (Palmaz or Palmaz-Schatz, Johnson and Johnson), which is covered by an Autologous Vein graft. After successful experimental implantation, we report here the immediate results of the percutaneous implantation of AVGCS in 7 patients with coronary artery disease (6 de novo lesions and 1 bailout case). The results of this preliminary study indicate that the preparation of the AVGCS is easy and feasible. The implantation of the AVGCS was uncomplicated, and the immediate angiographic results were excellent. This new type of coated stent may be useful in addressing current limitations of balloon angioplasty.
Konstantinos Toutouzas - One of the best experts on this subject based on the ideXlab platform.
-
Autologous Vein graft-coated stents for the treatment of thrombus-containing coronary artery lesions
Catheterization and cardiovascular diagnosis, 1997Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Recent studies have shown that stents may have a potential role in the treatment of thrombus-containing lesions. We report on the application of an Autologous Vein graft-coated stent (AVGCS) as the primary therapeutic modality for acute myocardial infarction in 10 patients. AVGCS delivery and deployment were successful and uneventful. Mean minimal lumen diameter and TIMI trial flow grade increased significantly (from 0.04 +/- 0.09 mm pre-AVGCS to 3.02 +/- 0.32 mm post-AVGCS, and from 10 patients with flow grade 0-1 pre-AVGCS to 10 patients with flow grade 3 post-AVGCS, respectively). Ten-day angiogram revealed maintenance of the immediate results. Nine patients had a negative exercise stress test 2 mo post-AVGCS, and at a mean follow-up of 30 +/- 7 weeks, all 9 were symptom-free. One patient, 3 wk after implantation and while being hospitalized for hypovolemic shock, developed recurrent infarction. These favorable preliminary outcomes suggest that AVGCS may play a useful role in the treatment of thrombus-containing lesions.
-
Stents wrapped in Autologous Vein: an experimental study.
Journal of the American College of Cardiology, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Panayiotis Karayannakos, Pavlos Toutouzas, Michael M. Gravanis, Keith A. RobinsonAbstract:Abstract Objectives. A new type of coated stent, consisting of a conventional stent covered by an Autologous Vein graft, was developed at our institution. Background. Coated stents are under investigation to address stenting limitations. However, experimental implantation of coated stents covered by Autologous tissue has not been reported. Methods. An Autologous Vein graft was removed and carefully prepared. Subsequently, a Palmaz stent was covered by the Vein graft both internally and externally. Twenty-seven stents were implanted in the normal iliac arteries of 27 pigs weighing 18 to 33 kg. In 15 of the pigs, 15 noncoated Palmaz stents were implanted in the contralateral artery; these animals served as the control group. The animals were followed up angiographically for a period ranging from 7 days to 6 months. At the time of death, the stented segments were removed, and histomorphometric analysis was performed. Results. Autologous Vein graft-coated stent preparation and implantation was feasible and uncomplicated. In both stents, angiographic follow-up revealed the absence of thrombosis, except for two cases of subacute thrombosis in the control group. The thickness of the intimal layer was greater in the coated stents and seems to be due to the existence of the internal Vein layer ([mean ± SD] 0.57 ± 0.12 vs. 0.27 ± 0.13 mm, p = 0.001). The arterial media of the coated stent segments was thinner than that in the control group (0.14 ± 0.03 vs. 0.18 ± 0.01 mm, p = 0.02). Conclusions. The Autologous Vein graft-coated stent seems to be nonthrombogenic, and only minimal hyperplasia was observed in the pigs. Further studies are needed to explore the efficacy of this technique in humans.
-
Autologous Vein graft-coated stent for treatment of coronary artery disease.
Catheterization and cardiovascular diagnosis, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Acute or subacute thrombosis and late restenosis remain the main limitations of permanent stenting. In an effort to address these limitations, an Autologous Vein graft-coated stent (AVGCS) was developed at our institution. This stent consists of a conventional stent (Palmaz or Palmaz-Schatz, Johnson and Johnson), which is covered by an Autologous Vein graft. After successful experimental implantation, we report here the immediate results of the percutaneous implantation of AVGCS in 7 patients with coronary artery disease (6 de novo lesions and 1 bailout case). The results of this preliminary study indicate that the preparation of the AVGCS is easy and feasible. The implantation of the AVGCS was uncomplicated, and the immediate angiographic results were excellent. This new type of coated stent may be useful in addressing current limitations of balloon angioplasty.
Charalambos Vlachopoulos - One of the best experts on this subject based on the ideXlab platform.
-
Autologous Vein graft-coated stents for the treatment of thrombus-containing coronary artery lesions
Catheterization and cardiovascular diagnosis, 1997Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Recent studies have shown that stents may have a potential role in the treatment of thrombus-containing lesions. We report on the application of an Autologous Vein graft-coated stent (AVGCS) as the primary therapeutic modality for acute myocardial infarction in 10 patients. AVGCS delivery and deployment were successful and uneventful. Mean minimal lumen diameter and TIMI trial flow grade increased significantly (from 0.04 +/- 0.09 mm pre-AVGCS to 3.02 +/- 0.32 mm post-AVGCS, and from 10 patients with flow grade 0-1 pre-AVGCS to 10 patients with flow grade 3 post-AVGCS, respectively). Ten-day angiogram revealed maintenance of the immediate results. Nine patients had a negative exercise stress test 2 mo post-AVGCS, and at a mean follow-up of 30 +/- 7 weeks, all 9 were symptom-free. One patient, 3 wk after implantation and while being hospitalized for hypovolemic shock, developed recurrent infarction. These favorable preliminary outcomes suggest that AVGCS may play a useful role in the treatment of thrombus-containing lesions.
-
Stents wrapped in Autologous Vein: an experimental study.
Journal of the American College of Cardiology, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Panayiotis Karayannakos, Pavlos Toutouzas, Michael M. Gravanis, Keith A. RobinsonAbstract:Abstract Objectives. A new type of coated stent, consisting of a conventional stent covered by an Autologous Vein graft, was developed at our institution. Background. Coated stents are under investigation to address stenting limitations. However, experimental implantation of coated stents covered by Autologous tissue has not been reported. Methods. An Autologous Vein graft was removed and carefully prepared. Subsequently, a Palmaz stent was covered by the Vein graft both internally and externally. Twenty-seven stents were implanted in the normal iliac arteries of 27 pigs weighing 18 to 33 kg. In 15 of the pigs, 15 noncoated Palmaz stents were implanted in the contralateral artery; these animals served as the control group. The animals were followed up angiographically for a period ranging from 7 days to 6 months. At the time of death, the stented segments were removed, and histomorphometric analysis was performed. Results. Autologous Vein graft-coated stent preparation and implantation was feasible and uncomplicated. In both stents, angiographic follow-up revealed the absence of thrombosis, except for two cases of subacute thrombosis in the control group. The thickness of the intimal layer was greater in the coated stents and seems to be due to the existence of the internal Vein layer ([mean ± SD] 0.57 ± 0.12 vs. 0.27 ± 0.13 mm, p = 0.001). The arterial media of the coated stent segments was thinner than that in the control group (0.14 ± 0.03 vs. 0.18 ± 0.01 mm, p = 0.02). Conclusions. The Autologous Vein graft-coated stent seems to be nonthrombogenic, and only minimal hyperplasia was observed in the pigs. Further studies are needed to explore the efficacy of this technique in humans.
-
Autologous Vein graft-coated stent for treatment of coronary artery disease.
Catheterization and cardiovascular diagnosis, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Acute or subacute thrombosis and late restenosis remain the main limitations of permanent stenting. In an effort to address these limitations, an Autologous Vein graft-coated stent (AVGCS) was developed at our institution. This stent consists of a conventional stent (Palmaz or Palmaz-Schatz, Johnson and Johnson), which is covered by an Autologous Vein graft. After successful experimental implantation, we report here the immediate results of the percutaneous implantation of AVGCS in 7 patients with coronary artery disease (6 de novo lesions and 1 bailout case). The results of this preliminary study indicate that the preparation of the AVGCS is easy and feasible. The implantation of the AVGCS was uncomplicated, and the immediate angiographic results were excellent. This new type of coated stent may be useful in addressing current limitations of balloon angioplasty.
